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Abstract Neutrophils are the foot soldiers of the immune
system. They home in to the site of infection and kill
pathogens by phagocytosis, degranulation, and the release
of web-like structures called neutrophil extracellular traps
(NETs) that trap and kill a variety of microbes. NETs have
been shown to play a multitude of additional roles in im-
munity but have also been implicated in inflammatory and
autoimmune disease. Here, we discuss the role of NETs in
these various contexts with a particular emphasis on the
molecular mechanisms that regulate NET release and clear-
ance. We highlight the comprehensive concepts and explore
the important open questions in the field.
Neutrophils are the major antimicrobial phagocytes of the
innate immune system. Along with eosinophils, basophils,
and mast cells, they comprise the granulocyte lineage. In the
absence of infection, these short-lived, terminally differentiat-
ed cells will leave the bone marrow and die in the confines of
the bloodstream. Upon infection, tissue-resident macrophages
and other sentinel cells, secrete inflammatory cytokines and
chemoattractants that are able to recruit and prime neutrophils.
In response to these molecules, neutrophils leave the blood-
stream and invade the infected tissues in a selectin- and
integrin-mediated process known as extravasation. They are
one of the first effector cells to arrive at the site of
infection and play critical roles in pathogen clearance,
recruitment, and activation of other immune cells and
tissue repair. Neutrophils employ three major strategies to
combat microbes: phagocytosis, degranulation, and the re-
lease of neutrophil extracellular traps (NETs) [1–3]. In this
review, we focus on the mechanisms that regulate the release
of NETs during infection and disease. We also cover various
aspects of NET function in these contexts.
Neutrophil antimicrobial strategies
Neutrophils are equipped with cytokines and an arsenal of
highly reactive, short-ranged antimicrobial proteins that ex-
hibit broad specificity and can be equally toxic to microbes
and host cells alike. Therefore, these antimicrobials are stored
in specialized vesicles known as granules and are deployed in
a rapid and spatiotemporally regulated manner [4]. Four dif-
ferent types of neutrophil granules are described to date:
primary or azurophilic granules that among other factors
contain myeloperoxidase (MPO), neutrophil elastase (NE),
cathepsin G, lysozyme and defensins. The secondary or spe-
cific granules contain mainly antimicrobials such as
lactoferrin and lysozyme, while the tertiary or gelatinase gran-
ules contain few antimicrobials but store metalloproteases
such as gelatinase. Finally, secretory granules carry cytokines
and important phagocytic receptors that are exposed to the
neutrophil surface upon priming and fusion of these granules
with the plasma membrane [5, 6]. During phagocytosis, neu-
trophils engulf and take up microbes into specialized com-
partments known as phagosomes in a receptor-mediated,
clathrin-independent process. Fusion of neutrophil granules
with the phagosome results in the formation of a
phagolysosome, allowing for the assembly of the nicotin-
amide adenine dinucleotide phosphate (NADPH) oxidase
complex Nox2. The NADPH oxidase is a transmembrane
multiprotein complex that transfers electrons to molecular
oxygen, to generate superoxide anions into the lumen of the
phagolysosome [7]. This highly oxidative environment in
combination with the exposure to antimicrobial factors leads
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to the inactivation and killing of ingested microbes [8].
Degranulation involves the fusion of granules with the plasma
membrane and the release of cytokines and antimicrobial
contents into the extracellular space. These molecules help
coordinate the immune response and control pathogens extra-
cellularly [9–11]. Azurophilic granules lack the soluble N-
ethylmaleimide-sensitive factor attachment protein receptors
(SNAREs) that would direct them to fuse with the plasma
membrane [12]. The contents of these granules are either
deployed inside the phagosome or are released extracellularly
via the third antimicrobial strategy in the neutrophil repertoire:
the formation of NETs.
NETs are web-like structures that are composed of
decondensed chromatin in complex with over 30 different
neutrophil proteins that can capture, neutralize, and kill a
variety of microbes. These large extracellular structures
provide a physical barrier to prevent microbial dissemina-
tion and increase the local concentration of antimicrobial
effectors [13–15]. Aside from infection, NETs have been
recently found to regulate B cell function in the spleen
[16] and to play a role in various sterile diseases, such as
autoinflammation, autoimmune disease. An increasing
number of bacteria, fungi, viruses, and protozoan parasites
have been shown to induce NETs. Deficiencies leading to
impaired NET formation result in high susceptibility to
opportunistic infections in humans and mouse models and
imply a significant contribution of NET formation in
antimicrobial defense. In addition to NETosis, these defi-
ciencies disrupt other neutrophil functions such as phago-
cytic killing, making it difficult to define the importance
of NETs in the larger context of infection. This raises the
necessity for dissecting the molecular mechanisms that
regulate NETosis.
NETosis appears to be tightly regulated and dysregulation has
been implicated in severe autoimmune and autoinflammatory
disease. Below, we discuss the molecular mechanisms
that lead to release of NETs, taking into consideration
the differences between different physiological stimuli in
infection and highlighting the importance of tight regu-
lation of NET formation in autoimmunity and sterile
inflammation.
NET formation and clearance
To date, two major NET release mechanisms have been
described. In the first mechanism, neutrophils release
NETs via a slow lytic cell death mechanism. This appears
to be a major route for NET release. In addition, Pilsczek et
al. have described that a small number of neutrophils rapidly
expulse their nuclear content via vesicular secretion, yield-
ing NETs and live intact cytoplasts that continue to crawl
and digest microbes [17].
NETosis via cell death
The first sign of NETosis via the cell death mechanism is a
change in the morphology of the nucleus, which loses its
characteristic lobulated architecture. Subsequently, nuclear
membranes disassemble and chromatin decondenses into
the cytoplasm while the plasma membrane remains intact.
Finally, the plasma membrane bursts and the NETs are
released [13] (Fig. 1b). This process is irreversible and is
dependent on reactive oxygen species (ROS) such as super-
oxide that is generated by the NADPH oxidase Nox2.
Neutrophils from chronic granulomatous disease (CGD)
patients who bear mutations that disrupt the activity of the
Nox2 enzyme, fail to form NETs [18, 19]. In addition,
several enzymes that regulate Nox2 activity such as protein
kinase C (PKC) isoforms and MAPK kinases have been
implicated in NET formation [20, 21]. However, the recep-
tors that trigger NET release and the molecular mechanisms
by which ROS drives this process remain poorly under-
stood. Superoxide spontaneously dismutates to hydrogen
peroxide. MPO consumes H2O2 to generate hypochlorite
and other halide ions [22]. MPO is also required for death-
mediated NETosis but the mechanism of action has not yet
been fully uncovered. The current evidence suggests that the
downstream oxidant products of MPO are not involved in
NETosis, as they fail to induce NET release and pharmaco-
logical inhibitors of the enzyme only slow down NETosis
[23]. Moreover, NET formation is abrogated only in patients
who are completely deficient in MPO. Experiments with
neutrophils from patients with partial MPO deficiency show
that even 5 % MPO activity is sufficient for NETosis [23].
MPO appears to drive NETosis independently from its en-
zymatic activity in a mechanism that involves synergy with
NE. In response to ROS, the neutrophil-specific protease
escapes from azurophilic granules into the cytoplasm and
translocates to the nucleus where it partially degrades his-
tones, the proteins that package DNA. This process drives
the initial relaxation and decondensation of chromatin [24]
(Fig. 2). Pharmacological inhibition of NE activity blocks
NET formation and mice lacking NE fail to form NETs in a
pulmonary model of Klebsiella pneumoniae infection.
Subsequently, MPO associates with chromatin and pro-
motes chromatin relaxation independent of the enzymatic
activity. MPO and NE synergize to drive massive chromatin
decondensation [24]. This two-step mechanism ensures that
the antimicrobial components of NETs are not degraded by
NE during the early phase of decondensation since binding
to DNA downregulates the proteolytic activity. Furthermore,
a strong ROS burst, and the expression of MPO and NE are
hallmarks of neutrophils and help explain why extracellular
trap (ET) release is confined to neutrophils and closely
related granulocytes cells such as eosinophils and mast cells.
The paradigm of ROS- and protease-dependent chromatin
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decondensation is employed for ET formation in macro-
phages, albeit using different factors.
Alternative rapid release of NETs from live cells
during sepsis
NET release via cell death is a slow process and may leave
an open time window for microbes to establish an infection.
Interestingly, an alternative rapid mechanism for NET re-
lease has recently been described [17]. Neutrophils stimu-
lated in vitro with Staphylococcus aureus, exhibit a unique
form of rapid NET release that does not involve cell
death. Reportedly, neutrophils release vesicles containing
decondensed chromatin and granule antimicrobial proteins
in the extracellular space where they assemble into NETs.
This process occurs rapidly (5–60 min) in comparison to the
cell death mechanism (120–240 min) (Fig. 1b). Release
from live PMNs can also be triggered by Streptococcus
pyogenes. Both NET formation strategies are dependent on
TLR2 and complement factor 3 (C3). NET formation is
deficient in mice lacking either of these molecules. NET
release is restored by addition of wild-type mouse serum,
highlighting the importance of opsonization for bacteria-
triggered NETosis. However, TLR2 ligands and C3a are
not sufficient to induce NET release in isolated neutrophils,
suggesting that additional mediators or more complex
mechanisms of activation are involved [25].
Rapid NET release was also observed by intravital mi-
croscopy in mice that were treated with MIP-2 (CXCL2)
and intradermal infection of S. aureus or S. pyogenes. In
vivo, the majority of neutrophils releasing NETs were un-
dertaking a cell death-mediated pathway. These cells were
highly motile and were phagocytosing bacteria. In addition,
a minority of anuclear neutrophils had already released their
nuclear material and were crawling slowly, still able to
digest microbes [25]. Since neutrophils are terminally dif-
ferentiated cells with low transcriptional activity, loss of the
nucleus does not incapacitate these cells. On the contrary,
this alternative mechanism of NET release provides a mul-
titasking means for rapid extracellular antimicrobial action
while maintaining the capacity for phagocytosis.
NET formation in CGD immunodeficiency
ROS play a central role in cell death-mediated NET formation
since neutrophils fromCGD patients who carry mutations that
Fig. 1 Induction and release of NETs. a List of stimuli known to induce
NETosis. b Two mechanisms of NET release have been discovered: an
early rapid mechanism that takes 5–60 min after stimulation with S.
aureus or LPS in the presence of platelets, undertaken by a small subset
of neutrophils, yielding NETs and live cytoplasts that continue to phago-
cytose (left). First, the nuclear membranes separate and decondensed
chromatin is seen in the intermembrane space. Chromatin-containing
vesicles bud from the nucleus and accumulate below the plasma
membrane. Finally, NETs are formed through the degranulation of vesicle
content into the extracellular space and their assembly with decondensed
chromatin. The majority of neutrophils undertake a cell death-mediated
NETosis program that lasts from 2 to 4 h (right). First, the nucleus loses
its characteristic lobulated shape. Subsequently, the nuclear membranes
disintegrate and chromatin decondenses into the cytoplasm of the intact
cell where it mixes with the granular contents. Finally, the plasma mem-
brane ruptures and the NETs are released
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inactivate the NADPH oxidase [26], do not form NETs [18].
The high susceptibility of CGD patients to severe life-
threatening infections with opportunistic pathogens suggests
that NETs may play an important role in containing these
infections in healthy individuals. However, the central role
of ROS in other essential neutrophil antimicrobial functions
such as phagocytic killing makes it difficult to draw conclu-
sions on the contribution of NETs in immune defense, from
the severity of CGD immune deficiency alone. Rather, the role
of NETs in the context of CGD has been inferred indirectly.
Importantly, the restoration of NADPH activity by gene ther-
apy was sufficient to completely eradicate systemic aspergil-
losis in a CGD patient [19]. Experiments exploring the mech-
anism of neutrophil clearance against the Aspergillus strain
recovered from the patient showed that the genetically mod-
ified neutrophils isolated from the patient killed the pathogen
mostly via NETosis. The importance of NETs was further
highlighted by the observation that the restoration of NET
formation in these CGD neutrophils enabled them to clear
both the Aspergillus conidia and hyphae that due to their large
size are resistant to killing via phagocytosis [19, 27].
MPO deficiency and the role of NETs in fungal infections
In contrast to CGD, MPO deficiencies are associated with
more complex clinical symptoms. The majority of the pa-
tients that are classified as MPO deficient bear mutations
that result only in a partial deficiency [28]. As MPO is
among the most abundant neutrophil proteins, low levels
of the protein in these healthy individuals are sufficient for
proper neutrophil function. Only a small subset of patients is
completely deficient in mature MPO protein and activity.
These completely deficient MPO individuals are susceptible
to chronic candidiasis and at rare occasions they present
severe systemic infection with opportunistic, often fungal,
pathogens that may render them clinically indistinguishable
Fig. 2 Molecular mechanisms of NET release. To date, few receptors
have been implicated in NET formation and little is known about the NET
inducing ligands at a molecular level. Receptor engagement involves
activation of phospholipase C (PLC), MAPK kinase (MAPKK) pathways
and the activation of C (PKC). Assembly of the NADPH oxidase com-
plex Nox2 on the membrane of the phagolysosome leads to production of
reactive oxygen species (ROS) and acidification of the phagolysosome.
Via an unknown mechanism, ROS drives the translocation of neutrophil
elastase (NE) from the azurophilic (AZ) granules to the nucleus where it
proteolytically processes histones and initiates the relaxation of chroma-
tin. Subsequently, MPO associates with chromatin and synergizes with
NE to promote chromatin decondensation. Together with other granule
and cytoplasmic proteins, decondensed chromatin will eventually be
released as NETs
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from CGD patients. In other cases, completely MPO-
deficient individuals may present no symptoms [29, 30].
Only neutrophils derived from completely MPO-deficient
patients are unable to form NETs [23]. The susceptibility of
these patients to fungal infections is a more direct indication
that NETs play an important role in antifungal defense. The
difference in the degree of immune deficiency between
CGD and MPO deficient individuals can be explained by
comparing their ability to employ different antimicrobial
strategies to contain infections.
CGD neutrophils are unable to kill via phagocytosis and
NET formation, while completely MPO deficient neutro-
phils have diminished, yet adequate, phagocytic killing ca-
pacity but fail to form NETs. Many fungi are able to switch
between a small yeast form, which is needed for systemic
dissemination and a filamentous hyphal form that is adapted
for tissue invasion [31]. Hyphae are too large to be phago-
cytosed. Thus, the ability of NETs to eradicate the large
hyphae extracellularly renders them critical in host defense
against fungal infections. Accordingly, the susceptibility of
completely MPO-deficient patients to recurrent mild fungal
infections and rare severe systemic episodes appears to be
linked to the inability of their neutrophils to form NETs and
is an indication that NETs are critical for antifungal defense.
The difference in the severity of the immune deficiency
between CGD and MPO-deficient individuals illustrates that
in order to provide protection against a broad variety of patho-
gens, the innate immune system has developed several layers of
defense that under most circumstances can compensate for each
other. This concept may help explain why completely MPO-
deficient patients aremostly healthy but occasionally experience
rare sporadic episodes of systemic fungal infection. While most
localized fungal infections present low risk, systemic fungal
infections represent serious threats and are difficult to eradicate.
In the case of MPO-deficient neutrophils, phagocytosis appears
to complement for the lack of NET formation in most infections
[23]. This compensating mechanism may be overburdened
when neutrophils are challenged with pathogens that are resis-
tant to phagocytic killing such as fungal hyphae. Since
completely MPO-deficient patients can clear the yeast form by
phagocytosis, they are able to prevent dissemination and are at
low risk for systemic fungal infection. However, the inability to
clear hyphae via NETosis may lead to persistence of hyphae that
may overwhelm the immune system and eventually allow for
yeast dissemination and systemic infection.
Histone deimination
Several reports have implicated peptidylarginine deiminase 4
(PAD4) in NET formation [20, 32–34]. PAD4 drives
citrullination of histones, which is readily observed during
NET formation and is a useful marker for NETosis. However,
despite several reports on the subject [34–36], there are still
open questions over the requirement for PAD4 in NET forma-
tion. Wang et al. tested PAD4 against human leukemia 60 cells,
which are very poor NET producers, but while they detected
histone citrullination in neutrophil-derived NETs, they did not
test the ability of PAD4 inhibitors to block NET release in
neutrophils. Moreover, in studies involving PAD4 deficient
mouse neutrophils stimulated with IL-8 and Shigella flexneri,
WT neutrophils did not exhibit sufficient NET formation, to be
able to make quantitative comparisons with PAD4-deficient
neutrophils [35]. The requirement for PAD4 has been more
convincingly demonstrated in the context of influenza infection
(see below) [36], suggesting that the role of PAD4 in NETosis
may be dependent on the stimulus. Consistently, Neeli et al.
reported that PAD4 is regulated by specific isoforms of PKC.
While many stimuli, including calcium ionophores, activate
PKCζ, an inducer of PAD4, others such as phorbol myristate
acetate (PMA), a strong inducer of NETosis, activate PKCα, an
inhibitor of PAD4 [20]. Therefore, differential engagement of
PKC isoforms may potentially regulate differential neutrophil
fates. Evidently, histone citrullination may coincide with but
not necessarily be required for NETosis. Still, citrullinated
histones may serve as a diagnostic marker for the presence of
NETs in tissues (see “Rheumatoid arthritis” for further
discussion).
ETs by eosinophils, mast cells, and macrophages
Several studies have shown that extracellular chromatin traps
are not exclusively released by neutrophils. Eosinophils [37]
and mast cells [38] have also been reported to release ETs.
Yousefi et al. reported that release of ETs from eosinophils
is dependent on ROS production and drives the release of
mitochondrial DNA.Mitochondrial genes such as cytochrome
b oxidase subunit 1 or NADH dehydrogenase subunit 1 have
been found in eosinophil ETs. Furthermore, ET release is
independent of cell death. Release of eosinophil ETs upon
stimulation by LPS, eotaxin, and complement factor 5a has
been shown to require priming with IL-5 or IFN-γ [37].
Another feature that clearly distinguishes eosinophil ETs from
NETs is the timing of release, which is reportedly in a frame
scale of seconds post stimulation, rather than hours. The
requirement for ROS raises the question of whether the cell
can generate an oxidative burst in time to drive rapid mito-
chondrial expulsion.
Since mitochondrial DNA does not contain histones,
which are major antimicrobial proteins in NETs, the micro-
bicidal activity of ETs is attributed to eosinophil antimicro-
bial proteins such as eosinophil cationic protein. The con-
tribution of ETs to immunity in vivo has not been clearly
demonstrated since experiments that specifically block
ETosis in animal models have not been reported, aside from
a transgenic model of eosinophilia, which exhibits a mod-
erate survival advantage under cecal ligation [37].
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Mast cells are important granulocytes that drive the
allergic response. They have been shown to release ETs
via cell death in response to stimulation in a ROS-
dependent manner [38]. Mast cell-derived ETs (MCETs)
contain mast cell-specific antimicrobial proteases such as
tryptase and antimicrobial peptides such as cathelicidin
(LL-37). The release of MCETs promotes the release of
pro-inflammatory cytokines in psoriasis, in addition to T
cell-derived cytokines [39]. Both NETing neutrophils and
mast cells have been reported to release interleukin (IL)-
17 in response to stimulation with IL-23 and IL-1β,
signifying that inhibition of ET formation may be an
important anti-inflammatory strategy.
To date, one recent report has provided significant
evidence to suggest that macrophages may release ETs
in response to Mycobacterium tuberculosis [40]. As in
NET formation, a protease inhibitor (AAPV) blocked
DNA release in macrophages. Macrophages do not ex-
press NE and AAPV does not inhibit chymotrypsin elas-
tases [41] but may inhibit macrophage metaloelastase or
other similar proteases [42]. Further genetic analysis is
needed, accompanied by examination of histone process-
ing, in order to address whether the reported MET re-
lease involves a mechanism that is analogous to the
neutrophil cell death process.
NETs in infection
NETs display broad effectiveness against a variety of differ-
ent species of gram-positive and gram-negative bacteria,
fungi, parasites and viruses. On the other hand, experimental
data suggest that NET formation appears to be restricted to
specific microbes. The features that define potent NET
stimuli are not known. In the following chapter we summa-
rize the most common physiological NET stimuli and the
implications for the role of NETs during infection.
Do NETs kill?
NETs contain a wide range of antimicrobial factors that are
known to kill microbes [43, 44]. To date, NETs have been
shown to kill or inhibit the growth of several bacterial,
fungal, and parasite species. Some skepticism surrounding
NET killing is founded in plating-based techniques to detect
microbial killing, where NETs may have clumped microbes
without killing them and thus reduce the number of plated
colonies. One short study demonstrated that when these
samples were treated with nucleases after the killing assay
had been performed, the number of colonies in NET-treated
samples was restored to levels of untreated bacteria [45].
However, a growth inhibition assay of Candida albicans
and Aspergillus fumigatus by NETs that is based on fungal
enzymatic activity confirms the killing capacity of NETs.
This approach is insensitive to microbial clumping artifacts.
Given that different groups employ different techniques to
assess microbial killing and the fact that these assays are
challenging, it is with little doubt that conflicting reports
arise. However, there is a decent body of evidence to sup-
port the killing capacity of NETs against a broad range of
microbes.
Bacterial infections
A variety of gram-negative as well as gram-positive bacteria
have been shown to induce NET formation. S. flexneri is
trapped and killed by NETs, which contain NE that degrades
virulence factors such as IcsA and IpaB [13]. Furthermore,
despite studies reporting that nonpathogenic Escherichia
coli triggers NET release [46, 47] to date the only compel-
ling data about E. coli-induced NETosis stems from studies
where pathogenic E. coli strains were used [48]. The entero-
pathogenic strain WS2572 induces formation of NETs in
neutrophils isolated from the bone marrow of WT mice.
Interestingly NET formation is abrogated in neutrophils
from glutathione reductase (GSR)-deficient mice. GSR
maintains the reducing environment in the cytoplasm and
these data suggest that NET release may be sensitive to the
oxidative levels, where too high ROS may be inhibitory.
Furthermore, the mammary pathogenic E. coli strain P4
induces NET release from primary bovine neutrophils ex
vivo [49]. These observations suggest that microbial viru-
lence may be an important stimulus in NET induction, as it
may induce additional inflammatory cytokines that may act
as co-activators.
Interestingly, the gram-negative bacterium K. pneumoniae
is not sufficient to induce NETosis in isolated neutrophils ex
vivo, but is a good inducer of NETosis in a mouse lung
infection model [24]. NE-deficient mice, lacking the capacity
to form NETs, are more susceptible to infection with K.
pneumoniae [50], but this may be due to inefficient phagocyt-
ic killing as well as the absence of NETs. The role of NETs in
combating K. pneumoniae is further corroborated by studies
that dissect the antimicrobial capacity of NETs. NETs from
myeloid related protein 14 (MRP14) deficient neutrophils fail
to control K. pneumoniae in vitro and MRP14 knockout mice
are more susceptible to K. pneumoniae, which disseminate
more readily in the absence of MRP14 and support the role of
NETs as effectors against bacterial dissemination [51].
Similarly, the adenosine A2B receptor (A2BR) is an anti-
inflammatory receptor that is thought to suppress NET forma-
tion. A2BR deficient neutrophils show enhanced NET forma-
tion and increased K. pneumoniae killing and clearance
[52]. Consistent with an increase in NET release in vivo,
A2BR deficient mice exhibit increased survival rates in K.
pneumoniae infection.
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Streptococci are gram-positive bacteria that include non-
pathogenic commensal strains, and highly virulent patho-
genic strains. Pathogenicity depends on expression of viru-
lence factors that allow the bacteria to establish an infection
and evade the immune system. Recent studies have revealed
a complex interplay between some of these virulence factors
and NETs.
Infection with Streptococcus pneumoniae leads to
community-acquired pneumonia and invasive diseases
like meningitis and bacteraemia, whereas S. pyogenes is
the major causative agent in group A Streptococcus
(GAS) infections [53–55]. Likewise, S. pneumoniae and
S. pyogenes induce NET formation but have evolved
virulence mechanisms to evade NETs. Strikingly, it ap-
pears that neutrophils have also evolved to selectively
release NETs in response to these virulence factors. The
S. pyogenes virulence factor M1, modulates NET forma-
tion and confers resistance to NET killing. M1 induces
NETosis by associating with fibrinogen and forming a
complex that stimulates neutrophils. M1 mutant S.
pyogenes exhibit a decreased ability to induce NET for-
mation. Interestingly, although M1 increases NETosis, it
also confers bacterial resistance to NET-mediated killing
by sequestering and neutralizing the antimicrobial NET
component cathelicidin, known as LL-37 in humans and
mCRAMP in mice. Overexpression of M1 in susceptible
S. pyogenes strains renders them resistant to extracellular
killing, whereas the deletion ofM1 in invasive serotypes leads
to susceptibility towards killing by NETosis [56]. Importantly,
these observations suggest that bacteria may have evolved to
evade neutrophils by directing them to an antimicrobial pro-
gram that they are able to resist, at the expense of other
neutrophil strategies they are more susceptible to. Other such
examples of pathogen specific molecules that are able to
trigger NETosis are becoming apparent. α-enolase expression
on the surface of S. pneumoniae is sufficient to trigger NET
formation by binding to the neutrophil myoblast antigen
24.1D5. However, genetic ablation of the enolase does not
disrupt NETosis [57].
Furthermore, S. pneumoniae has evolved strategies to
escape NETs. In a passive manner, the polysaccharide cap-
sule reduces NET binding [58]. In addition, streptococci
also employ active strategies to counter NETs. The invasive
pneumococcus type TIGR4 expresses the DNase endA,
which enables escape from NETs, leading to increased vir-
ulence in vivo. Mice that were infected with endA-deficient
TIGR4 bacteria showed lower mortality compared with the
WT controls [59]. Similarly, the nuclease Sda1 in S.
pyogenes degrades NETs and promotes high virulence in
vivo [60, 61]. Mice that are infected with S. pyogenes that
lack Sda1 cannot degrade NETs and exhibit low bacterial
titers and reduced lesion size in vivo [61]. Furthermore GAS
M1T1 express the protease SpeB that degrades Sda1 and
eliminates the capacity to escape NETs. In mice infected
with M1T1, bacteria that disseminated to internal organs
accumulated mutations that inactivated the protease and
allowed for an active Sda1 [62]. These results suggest that
NETs act as physical barriers to prevent microbial dissem-
ination and exert a selective pressure on the bacteria to
degrade NETs in order to break away from the site of
infection and spread systemically. However, recent work
has also demonstrated that Sda1 degrades bacterial DNA
to prevent alerting the immune system via the pattern rec-
ognition receptor Toll-like receptor 9 (TLR9), indicating
that the virulence attributed to Sda1 cannot be attributed
solely to NET evasion [63].
Likewise, S. aureus is a good inducer of NETosis [13, 18]
and has also evolved a plethora of mechanisms to circumvent
NET killing. One strategy involves the expression of pore-
forming virulence factors that neutralize neutrophils and pre-
vent NET formation by triggering necrosis. Moreover, catalase
expression blocks the build-up of H2O2 and protects S. aureus
from oxidation intracellularly and by blocking NETosis extra-
cellularly [18]. Thus, neutrophils may have evolved their sec-
ondary rapid NET release mechanism that is independent of
ROS in order to engage S. aureus and other catalase positive
strains. NETs specifically degrade S. aureus virulence factors
and thereby help to contain tissue damage, but methicillin-
resistant S. aureus (MRSA) express extracellular nucleases for
biofilm dispersal and degradation of NETs [64]. Mice infected
with MRSA show increased mortality compared with controls
infected with a nuclease deficient strain, which is more sus-
ceptible to extracellular killing by neutrophils. These findings
suggest the potential of nuclease inhibitors for treatment of
MRSA infections.
The facultative intracellular bacterium M. tuberculosis is
capable to successfully evade the host immune system and
to establish latent infection. Although macrophages play a
key role during MTB infection, recent evidence has
underlined the importance of neutrophils in containing the
infection [65]. Interestingly, a recent study shows that the
virulent M. tuberculosis H37Rv and the low virulent strain
Mycobacterium canettii are sufficient to trigger ROS pro-
duction and NET formation in vitro [66]. However, while
NETs trapped M. tuberculosis, the bacteria were not killed,
suggesting that NETs may be important for physically
restricting M. tuberculosis. This hypothesis requires further
testing in animal models and human studies.
Fungal infections
As mentioned above, neutrophils play a crucial role in
containing fungal infections and NETs appear to be an
important part of the neutrophil antifungal arsenal.
However, to date, only a limited number of fungal species
have been tested for their ability to induce NETs and to be
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efficiently killed by them. C. albicans is the most common
fungal commensal microorganism with asymptomatic colo-
nization of the skin and mucosal surfaces in 30–50 % of the
human population. Moreover, Candida species are also
amongst the most prevalent opportunistic human pathogens
in immunocompromised individuals with a mortality of up
to 40 % [67, 68]. C. albicans virulence is strongly depended
on its dimorphic ability: The budding yeast stage is crucial
for systemic dissemination, whereas hyphae are needed for
persistence and tissue invasion [31]. Since hyphae are too
large to be phagocytosed, extracellular killing by release of
NETs is an ideal strategy to contain the hyphal form and a
number of studies have demonstrated that NETs are suffi-
cient to kill C. albicans yeast and hyphae [19, 69].
Efforts to characterize the antifungal components of NETs
led to the identification of calprotectin as major antifungal
agent in the response against C. albicans [43]. Calprotectin is
a cytoplasmic protein that is released via NETosis both as a
soluble molecule and bound to NETs, highlighting the impor-
tance of NETosis as a major route for secretion of soluble
factors alongside NET-bound antimicrobials. While
calprotectin is found associated with C. albicans in NETs,
direct contact of the protein with the microbe is not crucial
since calprotectin chelates Mn2+ and Zn2+ which are required
for C. albicans growth. The importance of calprotectin in
antifungal defense is highlighted by the high susceptibility
of calprotectin-deficient mice towards subcutaneous and pul-
monary candidiasis [43]. Calprotectin has also been shown to
be an important NET component in the defense against
Aspergillus nidulans as calprotectin deficient mice are more
susceptible to aspergillosis.
Interestingly, the protective effect of calprotectin is de-
pendent on the presence of both subunits of the heterodu-
plex between the S1008A and S1009A subunits that pro-
vides anti-A. nidulans protection in a dose-dependent man-
ner. At low doses calprotectin acts reversibly as a fungistat-
ic, whereas high doses, it leads to starvation and subsequent
killing of the fungus [27]. CGD patients suffer from fre-
quent Aspergillus infections due to abrogated ROS produc-
tion and insufficient extracellular killing via NETosis.
Patients that received gene therapy to restore NADPH oxi-
dase function and therefore NET release have been shown to
regain capacity to clear A. nidulans infections in a NET- and
calprotectin-dependent manner [19, 27].
Little is known about the upstream recognition events that
regulate NETosis in response to fungi. Induction of NETosis
by A. fumigatus is independent of viable fungus; inactivated
conidia and hyphae are sufficient to trigger NET release [70].
Interestingly, the ability of fungal morphotypes to induce
NETs appears to be influenced by different fungal surface
molecules. Bruns et al. proposed that conidia induce slightly
fewer NETs than hyphae because they express hydrophobin
RodA, a surface protein that renders them immunologically
inert. Thus, conidia may be better protected against neutro-
phils than hyphae, which do not bear RodA on the surface.
RodA-deficient A. fumigatus conidia induce NETs better than
wild-type hyphae suggesting that RodA exhibits an inhibitory
effect on NET formation by shielding yet unidentified NET
inducing elements in conidia. Consistently, A. fumigatus
conidia were shown to be killed primarily by phagocytosis
and not NETosis [71]. In contrast, another report has indicated
that A. nidulans conidia can be killed via NETs, albeit less
efficiently than hyphae [19]. One note of caution with regards
to the RodA studies is that NET formation was not assessed by
microscopy but by a total fluorescence assay, which may not
be able to distinguish between NETs and necrotic neutrophils
with condensed nuclei. Furthermore, the effect of RodA may
be indirect since RodA deficient conidia may be more fragile
andmore likely to induce NETosis, althoughBruns et al. show
that these mutants are more resistant to phagocytic killing.
While further studies are needed to fully understand the
contribution of NETs in the immune defense against fungal
infection, there is strong evidence that NETs constitute an
important antifungal innate immune strategy.
Viral infections
Neutrophils are not regarded as important effector cells
against viruses and few studies have examined the role of
NET formation in response to viral infection. Recently,
human immunodeficiency virus (HIV)-1 was shown to in-
duce NETosis via the cell death pathway, although the
requirement for ROS, MPO and NE was not addressed
[72]. NETs are able to capture and neutralize the negatively
charged HIV virions, significantly decreasing HIV infectiv-
ity. Thus, neutrophils and NETs may play important roles in
combating HIV. Interestingly, HIV is capable of manipulat-
ing neutrophil activation in order to suppress NET forma-
tion. Saitoh et al. demonstrated that HIV engages DC-SIGN
(CD209) on dendritic cells (DCs) with its envelope glyco-
protein gp120. Engagement of DC-SIGN leads to produc-
tion of IL-10 by DCs, which suppresses NET formation
[72]. Therefore, HIV not only takes advantage of DC-
SIGN on DCs for efficient infection of CD4+ T-cells via
the DC-T cell synapse, but also to evade NET killing. This
study impressively demonstrates a surprising feature of
NETs as antiviral effectors and the capacity of HIV to
coevolve and adapt to the innate immune response.
Other viruses modulate host responses in order to sup-
press NET formation. Feline leukemia virus (FeLV) inhibits
neutrophil activation by inhibiting the activation of PKC to
reduce ROS production. Progressive chronic FeLV infection
reduces neutrophil responsiveness to secondary stimulation
with Leishmania promastigotes due to exhaustive neutrophil
activation by FeLV, demonstrating that neutrophil activation
and NET induction can be modulated by viral infection [73].
520 Semin Immunopathol (2013) 35:513–530
Finally, the role of NETs in influenza infection has also
been explored. NETs are induced secondarily by influenza-
activated lung epithelium producing superoxide and H2O2
[74]. Moreover, while influenza has been shown to induce
NETs in the mouse lung, NET deficiency in PAD4 knockout
mice was not associated with an increase in viral titers and
susceptibility to infection [36].
Therefore, while few studies have addressed the role of
NETs in viral infection, given that many viruses elicit strong
neutrophil recruitment, there is enough evidence to suggest
that NETs may be implicated in antiviral defense.
Parasitic infections
To date, several studies have explored the potential role of
NETs in the immune response against protozoan parasites.
Circulating NET structures have been detected in the blood
of Plasmodium falciparum-infected children with uncom-
plicated malaria. NETs entangled parasitized erythrocytes
and throphozoites, while titers of antinuclear antibodies
(ANAs) were significantly above levels associated with
auto-immunity [75]. Thus, the presence of NETs and the
formation of ANAs may contribute to disease in children
and development of autoimmune phenotypes, but may also
induce immune protection in adults over time. Furthermore,
it is speculated that the presence of ANAs may lead to
hyporesponsiveness towards CpG oligonucleotide-based
malaria vaccines [75].
The role of NETs has also been explored in parasites
causing leishmaniasis. Leishmania parasites are the induc-
ing agents in a variety of leishmaniasis infections where,
depending on the species, the phenotype can range from
cutaneous and subcutaneous lesions to potentially lethal
visceral leishmaniasis (kala-azar). The two major parasite
stages, amastigotes that reside primarily in macrophages and
promastigotes found primarily in the sandfly vector, induce
formation of NETs ex vivo. This effect is observed in
promastigotes of Leishmania amozonensis, Leishmania ma-
jor, Leishmania chagasi, Leishmania major, and Leishmania
donovani as well as in amastigotes of L. amozonensis and
seems therefore to be an important defense-mechanism
against Leishmania spp. Induction of NETs by Leishmania
spp has been reported to be independent of NADPH oxidase
activity and ROS production. Entrapment in NETs leads to
decreased viability of the parasites, although authors of dif-
ferent studies conclude that the main function of NETs in
Leishmania infection is the immobilization of the parasite
and containment of the infection [76, 77].
With regards to the molecular recognition of these para-
sites, different groups report a conflicting role for the
promastigote surface glycolipid lipophosphoglycan (LPG) in
NETosis. Guimaraes-Costa et al. describe NET induction by
LPG and provide evidence that purified LPG triggers NET-
formation in a dose-dependent manner [77]. In contrast,
Gabriel et al. report that NET formation is independent of
LPG and the surface metalloprotease leishmanolysin (GP63),
showing that LPG-deficient L. donovani promastigotes induce
NET sufficiently. Furthermore, LPG protects the parasite
against killing by NETs since an LPG-mutant strain is more
susceptible NET-mediated killing [76]. Anti-histone antibod-
ies abrogate the killing capacity of NETs towards Leishmania
and addition of purified histone H2B kills the parasite effi-
ciently, highlighting the important role of histones as NET
antimicrobial effector proteins [77, 78]. Therefore, LPG may
shelter the parasite from NET antimicrobial histones.
NETs are also implicated in Toxoplasma gondii infection.
T. gondii is an obligate intracellular parasite that infects
many warm-blooded animals. It leads to asymptomatic in-
fections in immunocompetent hosts, but causes severe dis-
ease in immunocompromised individuals and is a significant
risk factor in pregnant women. T. gondii elicits NET forma-
tion in a strain-independent manner. Invasion of the parasite
is not needed to trigger NET release, since treatment with
cytochalasin D inhibits entry of the parasite into the host
cell, but has no effect on NET formation [79]. NETs kill
approximately 25 % of the entangled parasites, which in-
dicates that the primary function of NETs may be to phys-
ically contain the infection. In vivo, pulmonary infection
with Toxoplasma in mice leads to recruitment of neutrophils
and high levels of extracellular dsDNA in the broncho-
alveolar fluid, which are abrogated by neutrophil depletion.
In addition to mouse, human blood-derived neutrophils have
also been shown to produce NETs in response to T. gondii.
The Raf-MEK-ERK pathway is implicated in the induction
of NETs by T. gondii, which elicit strong phosphorylation of
ERK1/2. However, inhibition of ERK1/2 leads to a decrease
in NET formation, but not complete abrogation. Therefore
ERK1/2 activation augments NET formation, but is not
absolutely required [79].
Finally, Eimeria bovis that induces enteritis with intesti-
nal lesions in calves and young cattle is a strong inducer of
NETosis ex vivo. In fact, NET formation, 30 min
postinfection with E. bovis is more efficient as compared
to induction with PMA (3–4 h), which is considered to be a
strong pharmacological NET inducer [80]. Interestingly, the
induction of NETs is dependent on viable parasite particles.
Inactivated and homogenized E. bovis still induce NETs,
but at levels below PMA induction. The induction is de-
pendent on the NADPH oxidase since inhibition with
diphenylene iodoniumn reduced NET formation to back-
ground levels.
These studies suggest that NETs play an important role in
the defense against protozoan parasites. However, the avail-
able data indicate that NETs may be important primarily to
physically restrict the entrapped pathogens and secondarily
to kill them.
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NET formation and clearance in disease
NETs are a potent neutrophil defense mechanism and com-
plement the immune system’s capacity to fight infectious
diseases. However, defects and dysregulation of this sensible
process can lead to severe pathologies and autoimmune con-
ditions. Excessive NET formation and impaired clearance of
NETs have been shown to contribute to inflammation and
organ damage in autoimmune disorders. Furthermore, NETs
display a range of self-antigens and may promote production
of autoantibodies.
Autoimmunity
Systemic lupus erythematosus and ANCA vasculitis
Systemic lupus erythematosus (SLE) is a diverse autoimmune
disease characterized by skin rashes, and internal organ pa-
thology. SLE patients exhibit elevated levels of anti-neutro-
phil cytoplasmic antibodies (ANCAs), antibodies against his-
tones, DNA (ANAs) and ribonucleoproteins (RNP) that target
host tissues [81]. The most severe symptoms of SLE include
renal pathology. Long-term immunosuppressive therapy in-
creases the risk for infection and sepsis in SLE patients and
more targeted treatments are needed [82]. The recent implica-
tion of NETosis in SLE pathology helps explain the high
prevalence of neutrophil specific autoantigens in these dis-
eases [83]. During infection, NETs are a major source of
extracellular chromatin, neutrophil proteins and microbial
co-stimulatory adjuvants, and are therefore a primary suspect
as an antigenic source in SLE (Fig. 3).
Furthermore, the antimicrobial peptide LL-37, an impor-
tant NET component, greatly enhances the ability of DNA to
activate plasmacytoid DCs via TLR9 [84, 85]. Subsequently, a
low-density granulocyte subset in the blood of SLE patients
was found to undergo spontaneous NET formation ex vivo
[86, 87]. Autoimmune complexes targeting NET components
were detected in sera from SLE patients and induce NET
formation in neutrophils from healthy control donors [85]. In
turn, NETs induce pDCs to secrete IFN-α, which promotes
autoreactivity of antigen-presenting and antibody-producing
cells and SLE progression [85, 87]. IFN-α has been shown to
prime neutrophils to respond to autoimmune complexes by
releasing NETs, which in turn activate pDCs further [84, 85].
Low-density granulocytes in SLE patients may be neutrophils
primed by IFN. The origins of such a priming event and why it
afflicts only a subset of granulocytes remain unclear. High
density SLE neutrophils do not form NETs spontaneously and
require IFN priming to respond to challenge with autoimmune
complexes [85].
This positive feedback loop may play an important role in
autoimmune disease development in SLE and ANCA
vasculitis. Several clinical trials involving anti-IFN-I strate-
gies are underway [88]. Additionally, targeting NETs direct-
ly may provide a beneficial therapeutic strategy since stud-
ies have demonstrated that SLE patients who appear defec-
tive in NET clearance mechanisms exhibit higher autoanti-
body titers and are more likely to develop lupus nephritis.
Sera from these patients do not degrade NETs either due to
low DNase I activity, expression of DNase I inhibitors or
presence of autoantibodies protecting NETs against degra-
dation by DNase I [83, 89]. Moreover, in DNase I-deficient
mice, production of ANCAs and immune complex forma-
tion is detected in the kidneys and associates with severe
glomerulonephritis [90].
Interestingly, Campbell et al. have recently suggested that
the NADPH oxidase acts to inhibit disease pathogenesis.
NADPH oxidase deficient mice, incapable to form NETs that
were crossed to a strain of lupus-prone mice, developed SLE
symptoms, suggesting that NET formation is not implicated in
SLE pathogenesis [91]. However, the mouse MRL/ltr model
is in a not well-defined genetic background, making it difficult
to compare to NADPH oxidase deficient mice. In addition,
these mice do not generate neutrophil-specific ANCA anti-
bodies and thus pathogenesis does not seem to implicate
NETs. Mutations in the human LTR Fas receptor gene result
in the absence of DCs in humans. These patients are very rare
and show no symptoms of autoimmune disease. Furthermore,
there are no reports of CGD patients exhibiting autoimmune
disease, but a case report of one CGD patient and a few
mothers of CGD patients suffering from autoinflammatory
disease without any autoantibody titers.
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease
associated with chronic inflammation, primarily in the synovial
joints. NETs are abundant in synovial fluids (SF), rheumatoid
nodules, and skin of RA patients. High levels of citrullinated
proteins [92] and elevated titers of anticitrullinated peptide
antibodies (ACPAs) in the SF are RA diagnostic markers.
ACPA containing serum and SF induce NETosis in neutrophils
from RA patients and control neutrophils ex vivo [93].
Furthermore, citrullinated vimentin externalized through NET
formation and anticitrullinated vimentin autoantibodies from
RA patients induce NETosis. In this vicious circle, NETs
present autoantigens in the context of immunostimulatory mol-
ecules thereby enhancing further NET release.
RA patients show elevated levels of proinflammatory cy-
tokines such as IL-17A and TNF-α [94]. Whereas IL-17A or
TNF-α alone are not sufficient to induce NETosis in control
neutrophils, stimulation with LPS, IL-17A, or TNF-α was
sufficient to trigger NET release in RA neutrophils without
further priming in a ROS-dependent manner. Furthermore,
the presence of anti-IL-17A or anti-TNF-α neutralizing
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antibodies decreased NET formation in RA neutrophils incu-
bated with RA serum and the presence of both antibodies
together abrogated NET formation completely [93]. It is
unclear how IL-17 activates neutrophils since reports suggest
that these cells do not express the IL-17 receptor C which
forms a multimeric complex with IL-17 receptor A and is
required for IL-17 receptor signal transduction [95, 96].
Interestingly, Khandpur et al. describe a different NET
protein composition depending on the stimulus [93].
NETs induced with RA autoantibodies contain matrix-
metalloprotease-8 (MMP-8), histone H3 and vasodilator-
stimulated phosphoprotein, which are not found in
TNF-α-induced NETs. NETs triggered by PMA contain his-
tone H3 but not MMP-8 [43]. MMP8 plays critical roles in
tissue destruction in arthritis and cancer metastasis [97],
suggesting that NETs may be an important source of this
metalloprotease in these diseases. Other proteins have been
shown to be present in NETs independent of the specific
stimulus [93]. The concept that different stimuli may lead to
NETs with different components and different attributes is an
interesting one, and should be explored further.
RA patients show elevated PAD4 expression and high
levels of anti-PAD4 autoantibodies [92, 98, 99]. Khandpur et
al. report that NET formation is decreased in the presence of
anti-PAD4 neutralizing antibodies in human neutrophils ex
vivo [93]. However, a recent study showed that PAD4 is
dispensable for development of RA in amouse model of serum
transfer disease [100]. Therefore, while hypercitrullinatedNET
histones may represent an important source of citrullinated
proteins in the joint of RA patients, the role PAD4 plays in
the regulation of NET formation and disease progression re-
mains unclear. Accordingly, although the presence of
citrullinated proteins may be a good diagnostic marker for
monitoring NET release in RA joints, PAD4 may not prove
to be a good target for therapy.
Gouty arthritis
Gouty arthritis is the most common form of arthritis and is
caused by precipitation of uric acid in sodium containing
fluids as monosodium urate (MSU) needles. Deposition of
MSU needles in the SF leads to activation of the NALP3
Fig. 3 NETs are implicated in the onset of inflammatory and autoim-
mune diseases. (clockwise) Gouty arthritis: deposition of MSU needles
in the SF leads to release of IL-1β by monocytes and induction of IL-8,
with subsequent neutrophil recruitment. MSU needles induce release
of NETs that stimulate a feedback loop of IL-1β production by mono-
cytes. Deep vein thrombosis: fibrin and von Willebrand factor (vWF)
promote blood clotting and deposition of thrombi in the blood vessels.
Activated endothelial cells release IL-8 and ROS, thereby recruiting
neutrophils and triggering NET formation. NETs act as scaffolds for
thrombi in the circulation by interacting with coagulation factors,
platelets, and red blood cells (RBC). Systemic lupus erythematosus
(SLE): a subset of low-density granulocytes has been shown to
spontaneously release NETs in SLE patients. The NET component
LL-37 enhances the ability of naked DNA to activate plasmacytoid
dendritic cells (pDC) via toll-like receptor 9 (TLR9). pDCs subsequent-
ly secrete IFN-α that primes neutrophils to recognize autoimmune
complexes of antinuclear antibodies (ANA) and DNA and release
NETs. This feedback loop further activates pDCs and may contribute
to SLE progression. Cystic fibrosis (CF): NETs form into the sputum in
an NE-dependent manner. i Inhibiting NE in intact neutrophils would
prevent NET release, but NE is also important in decondensing chro-
matin extracellularly, which enhances sputum solubilization by thera-
peutic DNases. ii NE inhibition extracellular would prevent tissue
damage iii but would also interfere with sputum solubilization
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inflammasome and release of IL-1β by monocytes. IL-1β
induces the neutrophil chemoattractant IL-8, which recruits
neutrophils (Fig. 3). Importantly, MSU needles trigger NET
release in gouty arthritis [101]. NETs are spared from
opsonization with C-reactive protein and complement.
Thus, gouty-associated NETs are not targeted for clearance
through scavenger cells and may persist long enough to
contribute to chronic inflammation [99].
NETs in inflammation
Cystic fibrosis
Cystic fibrosis (CF) is a debilitating hereditary disease, which
is caused by a mutation in the CF transmembrane conductance
regulator ion channel which leads to high sputum viscosity
and sputum that is difficult to clear from the airways. The lack
of sputum clearance promotes bacterial colonization leading
to chronic airway inflammation and low life expectancy of the
affected individuals [102]. Sputum viscosity is caused by high
levels of decondensed extracellular DNA since treatment with
recombinant DNase promotes sputum solubilization and is a
palliative treatment for CF [103, 104]. Neutrophil antimicro-
bial proteins such as NE and MPO are also abundant in CF
sputum [105]. The above observations hinted that NETs may
be an important source of extracellular DNA in CF sputum.
Indeed several studies have now confirmed the abundance of
NETs in CF sputum microscopically and biochemically [106,
107]. Notably, a study claiming that NETosis in CF is trig-
gered by IL-8 in a ROS-independent manner has since been
retracted [107]. In our hands IL-8 alone is not sufficient to
induce NETs. (Metzler and Zychlinsky, unpublished data).
Neutrophil infiltration in the lung and release of NE is
thought to have detrimental effects on lung epithelium. NE
directly injures epithelial cells, alters mucus secretion and
upregulates expression of pro-inflammatory cytokines [108].
Therefore, extracellular NE release via NETosis may be an
important cause of lung tissue damage and disease progression
in CF. NE inhibitors have been explored as therapeutics but
recent studies suggest that the potential of this strategy should
be viewedwith caution. Recent findings show that althoughNE
contributes to airway tissue damage, most of it is bound to
chromatin [106]. DNA binding has been shown to dramatically
downregulate NE proteolytic activity. Moreover, as it is an-
chored to NETs the residual NE activity is more likely to be
directed against histones rather than host tissues as NE con-
tinues to degrade histones after NET release. Similarly to its
role in NET formation, NE-mediated histone degradation pro-
motes chromatin relaxation and decondensation. Ex vivo ex-
periments with CF sputum suggest that the ability of NE to
decondense extracellular chromatin is important for the effec-
tiveness of DNase therapy [106]. Treatment of CF sputum from
patients receiving DNase therapy with NE inhibitors blocks the
sputum solubilization. On the other hand, NE activity is re-
quired for cell death-mediated NET release and blocking NE
activity early may reduce the levels of extracellular DNA and
sputum viscosity. Considering these findings, the nature and
timing of administration of these molecules would have to be
carefully examined. Soluble NE inhibitors would be ideal for
blocking NETosis in CF patients who are not receiving DNase
therapy. However, since these patients suffer from chronic
infection, blocking NET formation may have adverse effects
on their ability to contain the infection. Therefore, although
promising, this field requires further study.
Deep vein thrombosis
Deep vein thrombosis (DVT) is caused by disturbances and
stagnation in venous blood flow. Awide range of conditions
is known to increase the risk for DVT such as pregnancy,
obesity, trauma and certain cancers. Importantly, NETs have
been shown to form scaffolds in circulation that promote
thrombus formation by interacting with the endothelium,
platelets, coagulation factors and red blood cells.
Consistently, depletion of neutrophils [109] or injection of
exogenous DNase I have been shown to prevent thrombus
formation in mouse models and humans [109, 110]. IL-8 and
ROS released from endothelial cells can recruit and trigger
neutrophils to form NETs, which in return activate and
damage the endothelium by binding of histones to endothe-
lial membranes [111] (Fig. 3). The release of Weibel–Palade
bodies from the endothelium and deposition of fibrin and
vonWillebrand factor (vWF) promotes blood coagulation by
formation of thrombus scaffolds. vWF and fibrin have a high
affinity for histones and therefore readily bind to NETs [112,
113]. Furthermore, histones have been shown to inhibit
anticoagulants in the plasma, thereby further promoting
thrombus formation [114].
Additionally, the interaction of NETs with platelets plays
an important role in NET-mediated thrombus formation.
Platelets aggregate on the NETs due to proteoloytic activa-
tion of platelet receptors via NE and cathepsin G [115, 116].
Notably, a subset of SLE patients with specific antiplatelet
autoantibodies is in high risk of DVT in what is known as
antiphospholipid (or Hughes) syndrome [117]. Deficiency
in NET clearance in lupus patients may lead to a prolonged
persistence of associated immune complexes [83].
These studies suggest that targeting NET release and
driving NET clearance may constitute important therapeutic
strategies to treat DVT.
Preeclampsia
Preeclampsia is a severe condition during pregnancy that
affects 1–2 % of pregnant women and is characterized by
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proteinuria, oedema and drastic elevation of blood pressure.
Untreated preeclampsia can develop into eclampsia accom-
panied by seizures, which can be life threatening for the mother
and the fetus [118]. Currently, the only treatment for pre-
eclampsia is the premature delivery of the baby. Preeclampsia
is associated with abundance of placental microdebris in the
maternal blood circulation. Interestingly, micro-debris has been
shown to activate neutrophils and stimulate the release of NETs
in a dose-dependent manner [119–121]. However, although IL-
8 is not sufficient to trigger NET release in isolated neutrophils
(Zychlinsky, unpublished data) the elevated levels of this cyto-
kine in preeclampsia recruit neutrophils and may be important
for priming them to respond to micro-debris [119]. The inter-
play between microdebris and IL-8 in neutrophil activation and
deciphering the role of NETs in preeclampsia remain to be
investigated.
Periodontitis
Periodontitis is a chronic inflammation of the periodontium
caused by bacteria in the gingival crevice. Neutrophil influx
leads to formation of a purulent crevicular exudate. This
exudate has been shown to contain NETs that are thought to
prevent bacterial spread to the gingival surface [122]. NETs
may have evolved as an alternative defense mechanism to
the host cells’ inability to phagocytose bacterial biofilms in
the gingival crevice. However, the concomitant presence of
phagocytosing neutrophils indicates that both strategies may
be complementary.
The role of NETs in cancer
The role of tumor-associated neutrophils (TANs) in cancer is
still unclear. A recent study suggests that neutrophils can be
programmed to promote (N2) or suppress tumor growth (N1)
according to the tumor environment [123]. The transforming
growth factor-β (TGF-β) plays a central role in determining
this neutrophil phenotype. TGF-β appears to polarize a pro-
tumor N2 neutrophil state that may upregulate tumor cell
proliferation. In contrast, inhibiting TGF-β leads to antitumor
N1 TANs that may target tumor cells and prevent tumor
growth. It is unclear how TGF-β affects neutrophil function
and in particular NET release, but TGF-β inhibition resulted
in upregulation of neutrophil activation and ROS suggesting
that NETosis would be favored.
Indeed, lung adenocarcinomas elicited in NE knockout
mice grow significantly slower than in WT mice suggesting
that NE promotes tumor cell proliferation [124]. This study
provides evidence that NE is taken up by tumor cells and
upregulates the PI3K pathway. However, the proliferation
effects of NE on these cells in vitro appear modest and
alternative mechanisms, such as changes in NET release,
may also play a role. Interestingly, NETs have been recently
visualized in pediatric Ewing sarcoma (ES) tumors [125].
NETs may kill tumor cells but they may also release NE
that is mostly bound to NETs. By sequestering NE, NETs
may prevent the uptake of NE by tumor cells and create
a cytotoxic antitumor environment. Given tumor variabil-
ity, the role of neutrophil and NETs in cancer will likely
be complex and specific to different tumor types and
stages.
NETs as modulators of the adaptive immune system
Interestingly, in addition to activating pDCs, NETs appear to
play wider immunomodulatory roles as they were recently
shown to regulate B cell function in humans. Upon coloni-
zation of the gut with microbiota, neutrophils infiltrate the
spleen marginal zone (MZ) and form NETs, in a process that
depends on IL-10 release by splenic sinusoidal endothelial
cells [16]. NETs interact with and activate B cells via the
release of B cell regulatory proteins: a proliferation-
inducing ligand, B cell-activating factor BAFF and IL-21.
NET-mediated B cell activation triggers class switching,
somatic hypermutation and antibody production. The au-
thors examined human neutropenic patients and found that
these patients express low IgG and IgM levels, indicating a
requirement of neutrophils in class switching. Close exam-
ination of the list of patients provided reveals that although
they are classified as neutropenic, they are in their majority
patients who are deficient in NE. In fact, most severe cyclic
neutropenias are caused by mutations in NE that promote
misfolding of the protein and premature neutrophil apopto-
sis due to the activation of the unfolded protein response
[126]. SCN patients are treated with GM-CSF, which re-
stores the number of mature circulating neutrophils.
However, these neutrophils are still deficient in NE. The
MZ of SCN patients was still infiltrated by neutrophils but
NETosis was severely diminished. These data further con-
firm the requirement of NE for NET formation [24] and
highlight the role of NETosis as a route for the release of
immunomodulatory molecules that affect innate and adap-
tive responses.
Conclusions
In summary, NETs are effective against a variety of mi-
crobes but may be critical against pathogens that are resil-
ient against phagocytosis. NETs appear to play a key role in
physically trapping microbes to prevent microbial dissemi-
nation. However, dysregulation of NET formation and clear-
ance appears to have detrimental effects. One common
underlying theme in the work we have covered is that
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spatiotemporal regulation is key to ensure proper neutrophil
function and health: NETs are beneficial in some places and
have detrimental effects in others. Timing is also important
since NET persistence causes adverse effects. Important
mechanisms must be in place at the subcellular and organ-
ismal level to ensure that NETs are made and cleared at the
right place and time. Understanding of the molecular mech-
anisms and the spatiotemporal dynamics that regulate NET
release and clearance in these various contexts, may pave
the way for the development of new therapeutics for a
number of human diseases
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